"One-stop-shop" staging: Should we prefer FDG-PET/CT or MRI for the detection of bone metastases?

European Journal of Radiology

Volumn 78, Issue 3, 2011, Pages 430-435

  Heusner, Till ^a   Gölitz, Philipp ^a   Hamami, Monia ^a   Eberhardt, Wilfried ^a   Esser, Stefan ^a   Forsting, Michael ^a   Bockisch, Andreas ^a   Antoch, Gerald ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Malignant melanoma; Non small cell lung cancer; PET CT; Staging; Whole body MRI

Indexed keywords

FLUORODEOXYGLUCOSE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOLOGIST; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79957919089     PISSN: 0720048X     EISSN: 18727727     Source Type: Journal    
DOI: 10.1016/j.ejrad.2009.10.031     Document Type: Article

References (38)

1. Stahl A, Wieder H, Piert M, Wester HJ, Senekowitsch-Schmidtke R, Schwaiger M. Positron emission tomography as a tool for translational research in oncology. Mol Imaging Biol 2004;6:214-24. (Pubitemid 39022759)
2. Schaefer JF, Schlemmer HP. Total-body MR-imaging in oncology. Eur Radiol 2006;16:2000-15. (Pubitemid 44193185)
3. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41:1369-79. (Pubitemid 30643379)
4. Beyer T, Townsend DW. Putting 'clear' into nuclear medicine: a decade of PET/CT development. Eur J Nucl Med Mol Imaging 2006;33:857-61.
5. Kohl G. The evolution and state-of-the-art principles of multislice computed tomography. Proc Am Thorac Soc 2005;2:470-6, 499-500.
6. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology 2007;242:360-85. (Pubitemid 46150968)
7. Muller-Horvat C, Radny P, Eigentler TK, et al. Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. Eur J Cancer 2006;42:342-50. (Pubitemid 43132889)
8. Eschmann SM, Friedel G, Paulsen F, et al. FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy. Eur J Nucl Med Mol Imaging 2002;29:804-8.
9. Jadvar H, Johnson DL, Segall GM. The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma. Clin Nucl Med 2000;25:48-51. (Pubitemid 30029920)
10. Antoch G, Vogt FM, Freudenberg LS, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 2003;290:3199-206. (Pubitemid 38020681)
11. Antoch G, Vogt FM, Bockisch A, Ruehm SG. Whole-body tumor staging: MRI or FDG-PET/CT? Radiologe 2004;44:882-8.
12. Daldrup-Link HE, Franzius C, Link TM, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 2001;177:229-36. (Pubitemid 32578088)
13. Takenaka D, Ohno Y, Matsumoto K, et al. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. J Magn Reson Imaging 2009;30:298-308.
14. Kumar J, Seith A, Kumar A, et al. Whole-body MR imaging with the use of parallel imaging for detection of skeletal metastases in pediatric patients with small-cell neoplasms: comparison with skeletal scintigraphy and FDG PET/CT. Pediatr Radiol 2008;38:953-62.
15. Pfannenberg C, Aschoff P, Schanz S, et al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer 2007;43:557-64. (Pubitemid 46177588)
16. Antoch G, Kuehl H, Kanja J, et al. Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology 2004;230:879-85. (Pubitemid 38252890)
17. Beyer T, Antoch G, Blodgett T, Freudenberg LF, Akhurst T, Mueller S. Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging 2003;30:588-96. (Pubitemid 36559838)
18. Beggs AD, Hain SF, Curran KM, O'Doherty MJ. FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy. Eur J Nucl Med Mol Imaging 2002;29:542-6.
19. Patz Jr EF, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993;188:487-90. (Pubitemid 23216276)
20. Schmidt GP, Baur-Melnyk A, Herzog P, et al. High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system. Invest Radiol 2005;40:743-53. (Pubitemid 41690430)
21. Schmidt GP, Schoenberg SO, Schmid R, et al. Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 2007;17:939-49. (Pubitemid 46766875)
22. Acland KM, O'Doherty MJ, Russell-Jones R. The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma. J Am Acad Dermatol 2000;42:606-11. (Pubitemid 30479883)
23. Eigtved A, Andersson AP, Dahlstrom K, et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med 2000;27:70-5. (Pubitemid 30097263)
24. Surti S, Kuhn A, Werner ME, Perkins AE, Kolthammer J, Karp JS. Performance of Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging capabilities. J Nucl Med 2007;48:471-80. (Pubitemid 47604933)
25. Larson SM, Schoder H. New PET tracers for evaluation of solid tumor response to therapy. Q J Nucl Med Mol Imaging 2009;53:158-66.
26. Cobben DC, Jager PL, Elsinga PH, Maas B, Suurmeijer AJ, Hoekstra HJ. 3′-18F-fluoro-3′-deoxy-l-thymidine: a new tracer for staging metastatic melanoma? J Nucl Med 2003;44:1927-32.
27. Bolus NE, George R, Washington J, Newcomer BR. PET/MRI: the blended-modality choice of the future? J Nucl Med Technol 2009;37:63-71, quiz 72-63.
28. Wehrl HF, Judenhofer MS, Wiehr S, Pichler BJ. Pre-clinical PET/MR: technological advances and new perspectives in biomedical research. Eur J Nucl Med Mol Imaging 2009;36(suppl. 1):S56-68.
29. Pichler BJ, Wehrl HF, Kolb A, Judenhofer MS. Positron emission tomography/magnetic resonance imaging: the next generation of multimodality imaging? Semin Nucl Med 2008;38:199-208.
30. Antoch G, Bockisch A. Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging 2009;36(suppl. 1):S113-120.
31. Schmid RA, Hautmann H, Poellinger B, et al. Staging of recurrent and advanced lung cancer with 18F-FDG PET in a coincidence technique (hybrid PET). Nucl Med Commun 2003;24:37-45.
32. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-94. (Pubitemid 27444031)
33. Effert PJ, Bares R, Handt S, Wolff JM, Bull U, Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 1996;155:994-8.
34. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-d-glucose. Radiology 1996;199:751-6.
35. Yeh SD, Imbriaco M, Larson SM, et al. Detection of bony metastases of androgenin-dependent prostate cancer by PET-FDG. Nucl Med Biol 1996;23:693-7. (Pubitemid 26342473)
36. Nakai T, Okuyama C, Kubota T, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2005;32:1253-8. (Pubitemid 41598715)
37. Ghanem N, Uhl M, Brink I, et al. Diagnostic value of MRI incomparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol 2005;55:41-55. (Pubitemid 40798487)
38. Kruger S, Buck AK, Mottaghy FM, et al. Detection of bone metastases in patients with lung cancer: (99m)Tc-MDP planar bone scintigraphy, (18)F-fluoride PET or (18)F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2009.